Could halting CAG expansions be a new treatment for HD?

Could halting CAG expansions be a new treatment for HD?

The gene MSH3 is getting a lot of attention in HD research lately. New findings suggest MSH3 lowering could halt CAG repeat expansions, offering a new therapeutic avenue.

Dr Sarah HernandezOctober 05, 2023

Tipping the balance; new insights into HD genetic modifiers

Tipping the balance; new insights into HD genetic modifiers

A new study from researchers at Thomas Jefferson University delves into the details of how genetic modifiers of Huntington’s disease work.

Dr Rachel HardingSeptember 01, 2023

Drug to treat movement symptoms of HD approved by FDA

Drug to treat movement symptoms of HD approved by FDA

The FDA has approved valbenazine, also known as INGREZZA, as a treatment for the movement symptoms of Huntington’s disease

Dr Leora Fox and Dr Rachel HardingAugust 22, 2023

Youthful competitors: young brain cells oust the old

Youthful competitors: young brain cells oust the old

Replacing cells with HD in the brain could be an effective treatment strategy. Recent work shows that glia injected into mouse brains take over and oust the older cells, but for a surprising reason - because of age, not HD!

Dr Sarah HernandezAugust 08, 2023

Updates from PTC Therapeutics and uniQure on their huntingtin-lowering trials

Updates from PTC Therapeutics and uniQure on their huntingtin-lowering trials

Both PTC Therapeutics and uniQure have shared updates from their respective clinical trials, testing different huntingtin-lowering approaches. We explore the data presented from both of these studies and what this means for HD family members.

Dr Leora Fox and Dr Rachel HardingJune 21, 2023

Huntington’s disease therapeutics conference 2023 - Day 3

Huntington’s disease therapeutics conference 2023 - Day 3

Check out research updates from Day 3 of the 2022 HD Therapeutics Conference #HDTC2023

Joel Stanton, Dr Rachel Harding, Dr Leora Fox, and Dr Tamara MaiuriMay 22, 2023

Start here!

Start here!

Huntington's disease research news. In plain language. Written by scientists. For the global HD community.

Professor Ed Wild, Dr Leora Fox, Dr Rachel Harding, Dr Sarah Hernandez, and Dr Jeff CarrollMay 22, 2023

Huntington’s disease therapeutics conference 2023 - Day 2

Huntington’s disease therapeutics conference 2023 - Day 2

Check out research updates from Day 2 of the 2022 HD Therapeutics Conference #HDTC2023

Joel Stanton, Dr Rachel Harding, Dr Leora Fox, and Dr Tamara MaiuriMay 04, 2023

Huntington’s disease therapeutics conference 2023 - Day 1

Huntington’s disease therapeutics conference 2023 - Day 1

Check out research updates from Day 1 of the 2022 HD Therapeutics Conference #HDTC2023

Joel Stanton, Dr Rachel Harding, Dr Leora Fox, and Dr Tamara MaiuriApril 26, 2023

PROOF-HD study of pridopidine ends with negative result

PROOF-HD study of pridopidine ends with negative result

The phase 3 trial missed its primary endpoint of slowing loss of function in Huntington’s disease

Professor Ed WildApril 25, 2023

Astrocytes: The new star in HD research?

Astrocytes: The new star in HD research?

A new article summarizes what the Huntington's disease field has found about a type of brain cell called an astrocyte. These star-shaped cells help keep brain cells healthy and could be leveraged for developing new HD therapeutics.

Dr Sarah HernandezApril 19, 2023